Clinical Trial 22344

• Overview

  Study Title:

  A Phase I Clinical Trial of an Infusion of Autologous gamma delta T cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients with Metastatic Castration Resistant Prostate Cancer

  Objective:

  Primary: To assess the safety and tolerability of autologous PSCA γδ-enriched CAR T cell product in patients with mCRPC and to identify the recommended phase 2 dose (RP2D). Secondary: To determine the preliminary efficacy of PSCA γδ-enriched CAR T cells in patients with mCRPC.

• Treatments

  Therapies:

  Cell Therapy; Chemotherapy (NOS)

  Medications:

  MSGV1-PSCA-8T28Z (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

• Inclusion Criteria

  Key Inclusion Criteria:
  • Men with metastatic castration-resistant prostate cancer (CRPC) to the bone with evidence of imaging progression based on the PCWG3 criteria.
  • Prior therapies with at least 2 lines of chemotherapy and one new androgen receptor targeted therapy (abiraterone, enzalutamide, apalutamide, or darolutamide).
  • For patients who are on zoledronic acid a booster dose of zoledronic acid is required if the last dose of zoledronic acid is >4 weeks prior to lymphodepletion chemo. If a patient is receiving denosumab, the next dose of denosumab needs to be changed to zoledronic acid and he needs to receive at least 1 dose of zoledronic acid prior to lymphodepletion chemotherapy. If a patient is not on zoledronic acid or denosumab, he needs to receive at least 2 doses of every 4 weeks of zoledronic acid prior to lymphodepletion chemotherapy. Zoledronic acid is recommended not to be resumed prior to week 8. After week 8, the resumption of zoledronic acid and the subsequent zoledronic acid treatment will be at the discretion of the treating physician.
  • No anticancer therapy (chemotherapy, biologic therapy, radiation or immunotherapy) in the 3 weeks before the T cell infusion (and all hematologic effects have resolved). No prior treatment with Radium 223 or Puvicto within 3 months of T cell infusion. No prior immunotherapy with checkpoint blockade (e.g., PD-1 inhibitor, PDL1 inhibitor, or CTL4- antagonist or similar agent) in the 6 months before the T cell infusion (and all clinically significant related side effects must be resolved).
  • Males at least 18 years of age.
  • ECOG performance status greater than or equal to 2 (or Karnofsky Performance Status greater than or equal to 70%).
  • Participants must have adequate organ and marrow function as defined by the protocol.
  • Life expectancy of at least 6 months.
  • The effects of CAR T cell infusion on the developing human fetus are unknown. Although patients who are eligible for this study will not have childbearing potential, any patient the treating doctor or investigator deems to have child fathering potential must agree to use adequate contraception from the time of screening to at least 6 months after administration of gamma delta enriched T cell infusion. Any female partner(s) with childbearing potential, of these participants, should also use adequate contraception during the same time period.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Additional Criteria will apply.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Known active hepatitis B infection, known history of hepatitis C or HIV infection.
  • Known dental issues like osteonecrosis of jaw that excludes the use of zoledronic acid.
  • Any of the following cardiac conditions: I) Clinically significant heart disease (New York Heart Association class 3 or 4) or symptomatic congestive heart failure. II) Myocardial infarction less than 6 months before enrollment. III) History of clinically significant ventricular arrhythmia or unexplained syncope that is not believed to be vasovagal in nature or due to dehydration. IV) History of severe non-ischemic cardiomyopathy with ejection fraction less than 20%. V) Findings on baseline ECG or ECHO that, in the opinion of the patient’s treating physician or investigator, would require medical intervention before anticancer therapy.
  • Active autoimmune disease (excluding autoimmune thyroid disease on a stable thyroid regimen). Such conditions include but are not limited to systemic lupus erythematous, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis.
  • Known or suspected leptomeningeal disease and patients with metastases to the brain stem, midbrain, pons, or medulla.
  • Known or suspected untreated brain metastases. Patients with radiographically stable, asymptomatic previously irradiated lesions are eligible provided patient is greater than 4 weeks beyond completion of cranial irradiation and greater than 3 weeks off of corticosteroid therapy at the time of study intervention.
  • Prior history of clinically significant seizure disorder (e.g., not including childhood febrile seizures).
  • Any concurrent active malignancies, defined as malignancies requiring any therapy other than expectant observation, because adverse events (AEs) resulting from these malignancies, or their treatment may confound our assessment of the safety of adoptive T cell therapy for ovarian cancer.
  • Any of the following within 28 days of first date of study treatment: I) Serious uncontrolled medical illness or disorder that in the opinion of the treating physician would make the patient ineligible for the study. II) Active uncontrolled infection (with the exception of uncomplicated urinary tract infection).
  • Prior history of pancreatitis.
  • Additional Criteria will apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.